Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

You are here: Industry Insights > GRF6021 Trial

News List

Alkahest Doses First Subject in Phase 2 GRF6021 Trial americanpharmaceuticalreview
December 05, 2018
Alkahest announced dosing of the first subject in a Phase 2 clinical trial of its proprietary human plasma fraction, GRF6021, for the treatment of Parkinson's disease with associated mild cognitive impairment or dementia....

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

About Us: About PharmaSources; Terms of Service; Privacy Policy; Event Data Sharing Notice; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Copyright 2006-2025 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 滬ICP備05034851號-182 滬公網(wǎng)安備31010402010101號
Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight January 2025

PharmaSources Customer Service

<style id="0yh66"></style>

<blockquote id="0yh66"><i id="0yh66"><video id="0yh66"></video></i></blockquote>

<cite id="0yh66"><rp id="0yh66"><form id="0yh66"></form></rp></cite>